FibroGen, Inc.
FGEN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $29,621 | $46,803 | $140,734 | $235,309 |
| % Growth | -36.7% | -66.7% | -40.2% | – |
| Cost of Goods Sold | $15,561 | $3,962 | $20,280 | $449,192 |
| Gross Profit | $14,060 | $42,841 | $120,454 | -$213,883 |
| % Margin | 47.5% | 91.5% | 85.6% | -90.9% |
| R&D Expenses | $95,692 | $266,473 | $296,791 | $387,043 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $49,330 | $86,483 | $124,688 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $19,454 | $12,606 | $0 | -$312,396 |
| Operating Expenses | $164,476 | $365,562 | $421,479 | $74,647 |
| Operating Income | -$150,416 | -$322,721 | -$301,025 | -$288,530 |
| % Margin | -507.8% | -689.5% | -213.9% | -122.6% |
| Other Income/Exp. Net | -$2,951 | -$501 | $7,729 | -$1,146 |
| Pre-Tax Income | -$153,367 | -$323,222 | -$293,296 | -$289,676 |
| Tax Expense | -$269 | -$252 | $358 | $347 |
| Net Income | -$47,579 | -$284,232 | -$293,654 | -$290,023 |
| % Margin | -160.6% | -607.3% | -208.7% | -123.3% |
| EPS | -0.48 | -2.92 | -3.15 | -3.15 |
| % Growth | 83.6% | 7.3% | 0% | – |
| EPS Diluted | -0.48 | -2.92 | -3.15 | -3.15 |
| Weighted Avg Shares Out | 100,044 | 97,303 | 93,582 | 92,349 |
| Weighted Avg Shares Out Dil | 100,044 | 97,303 | 93,582 | 92,349 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5,296 | $7,594 | $7,596 | – |
| Interest Expense | $8,247 | $8,095 | $1,440 | $1,075 |
| Depreciation & Amortization | $2,692 | $9,930 | $10,604 | $14,809 |
| EBITDA | -$142,428 | -$305,197 | -$282,825 | -$333,721 |
| % Margin | -480.8% | -652.1% | -201% | -141.8% |